Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00687297 · ClinicalTrials.gov registry record · Phase 2
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
A Phase 2 study of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by PrECOG.
- Completed
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
- 20
- Study locations
NCT00687297 is a Phase 2 study of Non-Small Cell Lung Cancer and Lung Cancer that has completed, run by PrECOG. The registered enrollment target is 162 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT00687297, a Phase 2 study of Non-Small Cell Lung Cancer and Lung Cancer, has completed, sponsored by PrECOG.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
- 20
- Study locations
Study Summary
It has been shown in previous studies that the ability to treat lung cancer could be significantly improved by not only targeting the tumor cells directly with chemotherapy, but also by cutting off the blood supply to the cancer cells. Blood vessels that supply the tumor are formed through a process called angiogenesis. Vandetanib is an investigational drug that acts by producing what is called an anti-angiogenic effect. An Anti-angiogenic effect is able to inhibit the development of new blood vessels required by tumors to survive by blocking the growth factors needed to form new blood vessels. The purpose of this study is to determine if the addition of vandetanib to a standard chemotherapy regimen will slow or stop the growth of the cancer for a longer period of time compared to the time period generally gained from the use of standard chemotherapy alone
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Placebo
- DRUG Docetaxel
- DRUG vandetanib induction
- DRUG Vandetanib maintenance
Study Locations (20)
Pennsylvania
- Abington Memorial Hospital - Abington
- Hematology & Oncology of NEPA - Dunmore
- Lancaster General Hospital - Lancaster
- Central PA Hematology & Medical Oncology Associaties - Lemoyne
- University of Pennsylvania - Philadelphia
New Jersey
- Ocean Medical Center - Brick
- Morristown Memorial Hospital - Morristown
- Cancer Institute of New Jersey - New Brunswick
- Riverview Medical Center - Red Bank
Florida
- Boca Raton Community Hospital - Boca Raton
- Lakeland Regional Cancer Center - Lakeland
Michigan
- St. Joseph Mercy Hospital- Ann Arbor - Ann Arbor
- West Michigan Cancer Center - Kalamazoo
Illinois
- SwedishAmerican Hospital - Rockford
Kansas
- Cancer Center of Kansas - Wichita
Louisiana
- Ochsner Clinic - New Orleans
Maryland
- Greater Baltimore Medical Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2008-04 |
| Est. Completion | 2011-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00687297
The ClinicalTrials.gov registry entry for NCT00687297 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (75% lower). The listed sponsor is PrECOG, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT00687297 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Pennsylvania, New Jersey, Florida.
Frequently Asked Questions
What is clinical trial NCT00687297 about?
NCT00687297 is a clinical study titled "Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer". It has been shown in previous studies that the ability to treat lung cancer could be significantly improved by not only targeting the tumor cells directly with chemotherapy, but also by cutting off the blood supply to the cancer cells. Blood vessels that supply the tumor are formed through a process...
What is the current status of trial NCT00687297?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2008-04. Estimated completion is 2011-04.
What conditions does trial NCT00687297 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Lung Cancer.
What interventions are being tested in trial NCT00687297?
The interventions under investigation include: Carboplatin (DRUG), Placebo (DRUG), Docetaxel (DRUG), vandetanib induction (DRUG), Vandetanib maintenance (DRUG).
Who is sponsoring clinical trial NCT00687297?
This trial is sponsored by PrECOG, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00687297 being conducted?
This trial has 20 study locations across Florida, Illinois, Kansas, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.